[go: up one dir, main page]

WO2011005681A8 - Inhibition de l'inflammation par des oligosaccharides du lait - Google Patents

Inhibition de l'inflammation par des oligosaccharides du lait Download PDF

Info

Publication number
WO2011005681A8
WO2011005681A8 PCT/US2010/040895 US2010040895W WO2011005681A8 WO 2011005681 A8 WO2011005681 A8 WO 2011005681A8 US 2010040895 W US2010040895 W US 2010040895W WO 2011005681 A8 WO2011005681 A8 WO 2011005681A8
Authority
WO
WIPO (PCT)
Prior art keywords
milk oligosaccharides
inhibiting inflammation
inflammation
inhibiting
oligosaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/040895
Other languages
English (en)
Other versions
WO2011005681A1 (fr
Inventor
Ardythe L. Morrow
David S. Newburg
Guillermo M. Ruiz-Palacios
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION
Cincinnati Childrens Hospital Medical Center
General Hospital Corp
Original Assignee
INSTITUO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION
Cincinnati Childrens Hospital Medical Center
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43429494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011005681(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2012519618A priority Critical patent/JP2012532195A/ja
Priority to DK10797669.8T priority patent/DK2451462T3/en
Priority to US13/382,323 priority patent/US9034847B2/en
Priority to CA2767043A priority patent/CA2767043C/fr
Priority to EP10797669.8A priority patent/EP2451462B1/fr
Priority to ES10797669.8T priority patent/ES2651067T3/es
Application filed by INSTITUO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION, Cincinnati Childrens Hospital Medical Center, General Hospital Corp filed Critical INSTITUO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION
Publication of WO2011005681A1 publication Critical patent/WO2011005681A1/fr
Publication of WO2011005681A8 publication Critical patent/WO2011005681A8/fr
Anticipated expiration legal-status Critical
Priority to US14/700,232 priority patent/US10098903B2/en
Priority to US15/998,799 priority patent/US11058697B2/en
Priority to US17/333,614 priority patent/US11324765B2/en
Priority to US17/736,468 priority patent/US12171773B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention a pour objet une méthode d'inhibition d'une inflammation chez un sujet comprenant l'administration d'oligosaccharides du lait ou de glycoconjugués contenant des oligosaccharides du lait.
PCT/US2010/040895 2009-07-06 2010-07-02 Inhibition de l'inflammation par des oligosaccharides du lait Ceased WO2011005681A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2012519618A JP2012532195A (ja) 2009-07-06 2010-07-02 乳オリゴ糖による炎症の阻害
DK10797669.8T DK2451462T3 (en) 2009-07-06 2010-07-02 Inhibition of inflammation with milk oligosaccharides
US13/382,323 US9034847B2 (en) 2009-07-06 2010-07-02 Inhibiting inflammation with milk oligosaccharides
CA2767043A CA2767043C (fr) 2009-07-06 2010-07-02 Inhibition de l'inflammation par des oligosaccharides du lait
EP10797669.8A EP2451462B1 (fr) 2009-07-06 2010-07-02 Inhibition de l'inflammation par des oligosaccharides du lait
ES10797669.8T ES2651067T3 (es) 2009-07-06 2010-07-02 Inhibición de la inflamación con oligosacáridos de la leche
US14/700,232 US10098903B2 (en) 2009-07-06 2015-04-30 Inhibiting inflammation with milk oligosaccharides
US15/998,799 US11058697B2 (en) 2009-07-06 2018-08-16 Inhibiting inflammation with milk oligosaccharides
US17/333,614 US11324765B2 (en) 2009-07-06 2021-05-28 Inhibiting inflammation with milk oligosaccharides
US17/736,468 US12171773B2 (en) 2009-07-06 2022-05-04 Inhibiting inflammation with milk oligosaccharides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22314509P 2009-07-06 2009-07-06
US61/223,145 2009-07-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/382,323 A-371-Of-International US9034847B2 (en) 2009-07-06 2010-07-02 Inhibiting inflammation with milk oligosaccharides
US14/700,232 Continuation US10098903B2 (en) 2009-07-06 2015-04-30 Inhibiting inflammation with milk oligosaccharides

Publications (2)

Publication Number Publication Date
WO2011005681A1 WO2011005681A1 (fr) 2011-01-13
WO2011005681A8 true WO2011005681A8 (fr) 2011-08-04

Family

ID=43429494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/040895 Ceased WO2011005681A1 (fr) 2009-07-06 2010-07-02 Inhibition de l'inflammation par des oligosaccharides du lait

Country Status (7)

Country Link
US (5) US9034847B2 (fr)
EP (2) EP3248605A1 (fr)
JP (1) JP2012532195A (fr)
CA (1) CA2767043C (fr)
DK (1) DK2451462T3 (fr)
ES (1) ES2651067T3 (fr)
WO (1) WO2011005681A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833165B2 (en) 2014-10-29 2023-12-05 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185931B1 (fr) 2007-09-07 2013-07-10 Children's Hospital Medical Center Utilisation des taux d'antigène sécréteurs, lewis et sialyle dans des échantillons cliniques comme prédicteurs de risque de maladie
WO2011005681A1 (fr) 2009-07-06 2011-01-13 Children's Hospital Medical Center Inhibition de l'inflammation par des oligosaccharides du lait
DK2576578T3 (en) 2010-06-01 2019-01-14 Glycom As Polymorphs of 2'-o-fucosyllactose and producing thereof
MY166946A (en) 2010-12-31 2018-07-25 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
MY165628A (en) 2010-12-31 2018-04-18 Abbott Lab Human milk oligosaccharides for modulating inflammation
MY180910A (en) 2010-12-31 2020-12-11 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
SG10201707519PA (en) 2010-12-31 2017-10-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MY192208A (en) 2010-12-31 2022-08-08 Abbott Lab Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
CN103501638A (zh) 2010-12-31 2014-01-08 雅培制药有限公司 包含人乳低聚糖和核苷酸的营养型组合物以及其治疗和/或预防肠病毒感染的用途
CN103442696B (zh) 2011-02-04 2016-09-21 加利福尼亚大学董事会 预防或抑制肠病的二唾液酸乳-n-四糖（dslnt）或其变体、异构体、类似物和衍生物
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
US10639319B2 (en) * 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP2836218A4 (fr) * 2012-04-13 2015-10-21 Trustees Boston College Compositions prébiotiques et leurs procédés d'utilisation
ES2795665T3 (es) 2012-09-14 2020-11-24 Abbott Lab Procedimientos para aumentar la funcionalidad cerebral utilizando 2-fucosil-lactosa
DK2708145T3 (en) * 2012-09-14 2016-07-18 Abbott Lab Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals
CN110679948A (zh) * 2012-12-20 2020-01-14 雅培制药有限公司 使用人乳寡糖用于调节炎症的营养制剂
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
WO2015077233A1 (fr) 2013-11-19 2015-05-28 Abbott Laboratories Procédés pour prévenir ou atténuer des réponses allergiques aiguës au moyen d'oligosaccharides de lait humain
EP2888950A1 (fr) * 2013-12-24 2015-07-01 Abbott Laboratories Procédés pour traiter, prévenir ou réduire une neuro-inflammation ou une déficience cognitive
PL2896628T3 (pl) 2014-01-20 2019-03-29 Jennewein Biotechnologie Gmbh Sposób wydajnego oczyszczania obojętnych oligosacharydów ludzkiego mleka (HMO) z fermentacji mikrobiologicznej
MY198632A (en) 2014-04-08 2023-09-11 Abbott Lab Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
WO2016040531A1 (fr) * 2014-09-09 2016-03-17 Glycosyn LLC Alpha (1,3) fucosyltransférases destinées à être utilisées dans la production d'oligosaccharides fucosylés
DK3212198T3 (en) * 2014-10-29 2021-03-29 Glycom As Synthetic composition and method for promoting mucosal healing
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
MX378680B (es) * 2015-03-05 2025-03-11 Soc Des Produits Nestle S A Star Composiciones para usar en la prevencion o el tratamiento de infecciones/inflamaciones gastrointestinales en infantes o niños pequeños.
EP3288389A4 (fr) * 2015-04-28 2018-10-10 Children's Hospital Medical Center Utilisation de compositions d'oligosaccharides pour améliorer la prise de poids
EP3334437A1 (fr) * 2015-08-25 2018-06-20 Kaleido Biosciences, Inc. Compositions de glycane et leurs utilisations
EP3368046B1 (fr) * 2015-10-28 2022-07-27 Glycom A/S Composition synthétique et procédé de modulation de la fonction cérébrale et du comportement
EP3490567A4 (fr) 2016-07-28 2020-03-18 Fonterra Co-Operative Group Limited Produit laitier et procédé associé
CN110475559A (zh) 2017-01-23 2019-11-19 赛诺维曾有限公司 一种含有唾液酸乳糖或其盐作为有效成分的用于预防或治疗退行性关节炎的组合物
US20200129534A1 (en) * 2017-04-07 2020-04-30 Children's Hospital Medical Center Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
CN111356461A (zh) * 2017-10-04 2020-06-30 加利福尼亚大学董事会 免疫调节性低聚糖
EP3716984B1 (fr) 2017-11-30 2024-03-20 Glycom A/S Mélange de hmos pour le traitement de la sensibilité au blé
WO2019106620A1 (fr) * 2017-11-30 2019-06-06 Glycom A/S Oligosaccharides du lait humain et compositions synthétiques de ceux-ci pour la modulation du microbiote
US11304966B2 (en) 2017-12-22 2022-04-19 Glycom A/S Composition comprising HMOs for preventing or reducing nociception
EP3801067A4 (fr) * 2018-06-01 2022-03-09 Evolve Biosystems Inc. Compositions et procédés pour favoriser la défense de l'hôte et stimuler, étendre et/ou réinitialiser des répertoires de lymphocytes t
BR112021011071A2 (pt) 2018-12-19 2021-08-31 Glycom A/S Composição e método para o tratamento de seres humanos utilizando dietas com baixo teor de fodmap
US20220054515A1 (en) * 2018-12-21 2022-02-24 Glycom A/S Composition and method for promoting intestinal barrier healing
WO2020210027A1 (fr) 2019-04-09 2020-10-15 Lupa Bio, Inc. Oligosaccharides immuno-modulatoires de traitement de la douleur
CN110038020A (zh) * 2019-04-23 2019-07-23 河南省农业科学院 唾液酸模拟物在制备抑制巨噬细胞感染或激活状态下所引起炎症的药物中的应用
KR20220066904A (ko) 2019-09-24 2022-05-24 프롤랙타 바이오사이언스, 인코포레이티드 염증 및 면역 질환의 치료용 조성물 및 방법
WO2022159705A1 (fr) * 2021-01-22 2022-07-28 Prolacta Bioscience, Inc. Formulations topiques de lait maternel
US11712445B2 (en) * 2021-04-30 2023-08-01 Sourabh Kharait Compositions and methods for improving gastrointestinal function in subjects with renal disease
WO2023059530A1 (fr) * 2021-10-04 2023-04-13 Dsm Nutritional Products, Llc Compositions d'oligosaccharides et procédés d'utilisation associés pour le traitement de maladies pulmonaires inflammatoires
CN118805901A (zh) * 2023-04-19 2024-10-22 科·汉森有限公司 3-岩藻糖基乳糖

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1246902A (en) 1969-03-27 1971-09-22 Boots Pure Drug Co Ltd Improvements in therapeutic agents
DK455088D0 (da) 1988-08-12 1988-08-12 Symbicom Ab Syntetiske receptoranaloger
US5874261A (en) 1988-09-02 1999-02-23 The Trustees Of The University Of Pennsylvania Method for the purification of glycosyltransferases
AU1926692A (en) 1991-04-19 1992-11-17 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for endothelial binding
JPH07509139A (ja) 1992-07-30 1995-10-12 インターナショナル　フラワー　ディベロップメンツ　プロプライアタリー　リミティド グリコシルトランスフェラーゼ酵素をコードする遺伝子配列およびその用途
US5874271A (en) 1992-08-21 1999-02-23 Takara Shuzo Co., Ltd. Human glycosyltransferase gene, compounds and method for inhibiting cancerous metastasis
EP0601417A3 (fr) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologiquement compatible et dégradable bloques de récepteur d'hydrate de carbone à base de polymère, procédé de leur préparation et leur utilisation
JPH08509467A (ja) * 1993-02-26 1996-10-08 ノルマーク，ヤーン・スタツフアン 細菌接着のインヒビターとしてのオリゴ糖グリコシドの使用
US5484773A (en) 1994-02-14 1996-01-16 Alberta Research Council Treatment of antibiotic associated diarrhea
DE69524386D1 (de) 1994-02-16 2002-01-17 Pharming Intellectual Pty Bv Isolierung von lactoferrin aus milch
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
NZ281041A (en) 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
US5750176A (en) 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
WO1995034663A1 (fr) 1994-06-13 1995-12-21 Banyu Pharmaceutical Co., Ltd. Gene codant la glycosyl-transferase et utilisation de ce gene
US5576300A (en) 1994-09-16 1996-11-19 Abbott Laboratories Method for inhibition of human rotavirus infection
US5545553A (en) 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5858752A (en) 1995-06-07 1999-01-12 The General Hospital Corporation Fucosyltransferase genes and uses thereof
JP2758856B2 (ja) 1995-06-15 1998-05-28 理化学研究所 セラミドグルコシルトランスフェラーゼ
WO1997027303A1 (fr) 1996-01-24 1997-07-31 Toyo Boseki Kabushiki Kaisha Alpha-1-6 fucosyltransferases
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5856159A (en) 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5821100A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene gtfb from Amycolatopsis orientalis
US5821097A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene GtfC from Amycolatopsis orientalis
US5821098A (en) 1996-09-13 1998-10-13 Eli Lilly And Company Glycosyltransferase gene gtfD from amycolatopsis orientalis
US5871983A (en) 1996-09-13 1999-02-16 Eli Lilly And Company Glucosyltransferase gene GTFE from amycolatopsis orientalis
CA2664150C (fr) 1996-09-17 2013-01-08 Kyowa Hakko Bio Co., Ltd. Procedes de production de nucleotides de sucre et de glucides complexes
US5922540A (en) 1996-12-20 1999-07-13 Eli Lilly And Company Monofunctional glycosyltransferase gene of Staphylococcus aureus
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US6132710A (en) 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US6087143A (en) 1997-09-05 2000-07-11 Eli Lilly And Company Glycosyltransferase gene gtfA from Amycolatopsis orientalis
US7244601B2 (en) 1997-12-15 2007-07-17 National Research Council Of Canada Fusion proteins for use in enzymatic synthesis of oligosaccharides
US5955282A (en) 1998-04-03 1999-09-21 Incyte Pharmaceuticals, Inc. Human galactosyltransferases
US6126961A (en) 1998-04-13 2000-10-03 Kross; Robert D. Composition and method for reducing the colonization of animal intestines by salmonella and other bacterial pathogens
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6238894B1 (en) 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
US6291435B1 (en) 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
US20030036070A1 (en) 1999-10-21 2003-02-20 Shukti Chakravarti Gene expression profiling of inflammatory bowel disease
WO2002018556A2 (fr) 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 8797, nouvelle galactosyltransferase humaine et ses applications
FI109811B (fi) 2000-09-26 2002-10-15 Medicel Oy Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä
AU3956002A (en) 2000-11-28 2002-06-11 Childrens Medical Center Determination of risk and treatment of complications of prematurity
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
RU2373769C2 (ru) 2003-10-24 2009-11-27 Н.В. Нютрисиа Синбиотическая композиция для детей
WO2005055944A2 (fr) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
EP1597978A1 (fr) 2004-05-17 2005-11-23 Nutricia N.V. Synergie de GOS et polyfructose
WO2006023229A2 (fr) 2004-07-27 2006-03-02 The Regents Of The University Of California Traitement de l'epilepsie par l'expression de st3gal-iii
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
ES2702631T5 (es) 2005-02-28 2023-03-22 Nutricia Nv Composición nutricional con prebióticos y probióticos
JP2008545437A (ja) 2005-06-06 2008-12-18 ワイス 炎症性腸疾患についての末梢血単核細胞の発現プロフィール
CN101415461A (zh) 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
CN101400267B (zh) 2006-02-10 2011-11-23 雀巢产品技术援助有限公司 寡糖混合物
AU2007235145B2 (en) 2006-03-31 2011-09-22 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2185931B1 (fr) 2007-09-07 2013-07-10 Children's Hospital Medical Center Utilisation des taux d'antigène sécréteurs, lewis et sialyle dans des échantillons cliniques comme prédicteurs de risque de maladie
EP2072052A1 (fr) * 2007-12-17 2009-06-24 Nestec S.A. Prévention d'infections opportunistes dans des sujets dont l'immunité est fragilisée
CA2745099C (fr) 2008-12-02 2017-11-07 Prolacta Bioscience, Inc. Compositions de permeat de lait humain et procedes de fabrication et d'utilisation de celles-ci
WO2011005681A1 (fr) 2009-07-06 2011-01-13 Children's Hospital Medical Center Inhibition de l'inflammation par des oligosaccharides du lait
EP2593466B1 (fr) 2010-07-12 2018-05-30 The Regents of The University of California Oligosaccharides de lait bovin
JP6129821B2 (ja) 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
CN103889239A (zh) 2011-10-18 2014-06-25 雀巢产品技术援助有限公司 用于促进肠血管生成和营养吸收和经肠喂养耐受性和/或预防和/或治疗肠炎、和/或肠损伤和手术后恢复的组合物
IN2014DN01468A (fr) 2011-10-18 2015-05-22 Nestec Sa
PT2768313E (pt) 2011-10-18 2015-10-14 Nestec Sa Complexos de derivados de hidratos de carbono-ferro hidrossolúveis, a sua produção e os medicamentos que os contêm
EP2836218A4 (fr) 2012-04-13 2015-10-21 Trustees Boston College Compositions prébiotiques et leurs procédés d'utilisation
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
EP3288389A4 (fr) 2015-04-28 2018-10-10 Children's Hospital Medical Center Utilisation de compositions d'oligosaccharides pour améliorer la prise de poids
PL3349763T3 (pl) 2015-09-14 2022-01-03 Glycom A/S Kompozycja do zastosowania w modulowaniu mikrobioty

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833165B2 (en) 2014-10-29 2023-12-05 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome

Also Published As

Publication number Publication date
US9034847B2 (en) 2015-05-19
US10098903B2 (en) 2018-10-16
US20150306120A1 (en) 2015-10-29
CA2767043C (fr) 2020-07-14
US20190099435A1 (en) 2019-04-04
WO2011005681A1 (fr) 2011-01-13
ES2651067T3 (es) 2018-01-24
EP2451462A1 (fr) 2012-05-16
EP3248605A1 (fr) 2017-11-29
US11058697B2 (en) 2021-07-13
US11324765B2 (en) 2022-05-10
EP2451462B1 (fr) 2017-09-06
US20230101412A1 (en) 2023-03-30
US20120202753A1 (en) 2012-08-09
US12171773B2 (en) 2024-12-24
EP2451462A4 (fr) 2012-12-12
JP2012532195A (ja) 2012-12-13
US20210283155A1 (en) 2021-09-16
DK2451462T3 (en) 2017-12-11
CA2767043A1 (fr) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2011005681A8 (fr) Inhibition de l'inflammation par des oligosaccharides du lait
EP2353116B8 (fr) Système de pompe à perfusion et procédés
EP2464411A4 (fr) Cathéter comprenant une réserve de fluide hydratant interne et/ou ensemble cathéter l'utilisant et son procédé de fabrication et/ou d'utilisation
IL217026A (en) A capsule, a beverage system and method for making a beverage, and a method for making a capsule
PL1946793T3 (pl) Zawór jednokierunkowy do medycznych przewodów infuzyjnych i tym podobnych
WO2012051344A3 (fr) Maintien de zones physiologiques définies multiples utilisant un contrôle prédictif de modèle
AP2012006265A0 (en) Methods and istallations for manufacturing biaxially oriented tubing and the tubing itself.
EP2720030B8 (fr) Système de gestion de médicaments et procédé l'utilisant
EP2526818B8 (fr) Ferrure pour une armoire aménagée pour les handicapés et armoire associée
EP2642700A4 (fr) Système empêchant la formation d'une boucle fermée et procédé empêchant la formation d'une boucle fermée
EP2411465A4 (fr) Procédé de préparation d'un copolymère hétérophasique et ses utilisations
IL201264A0 (en) Neuraminic acid derivatives and methods of manufacturing the same
EP2398511B8 (fr) Dispositif médical et son procédé de fabrication
WO2010056656A3 (fr) Synthèse de chlorhydrate de palonosétron cristallin
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
TWI563021B (en) Hydrophobic cellulosic substrates and methods for producing the same
EP2624776A4 (fr) Dispositifs, systèmes, et procédés permettant d'améliorer l'accès aux cavités cardiaques et vasculaires
IL208809A (en) Oligosaccharides containing disaccharide units and methods for preparing them
WO2010095044A3 (fr) Dispositif médical pourvu d'un revêtement retardant la dégradation
EP2637725A4 (fr) Port d'accès vasculaire et cathéter
EP2247427A4 (fr) Films artistiques et procédés de fabrication
AU2013207618A1 (en) Remote sensing in an implantable medical device
GB0814626D0 (en) The drink safe system
HK1185680A (en) Multi-phased and partitioned content preparation and delivery
AU2010209200B2 (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797669

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2767043

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012519618

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010797669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010797669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13382323

Country of ref document: US